Pathogenic fungi are a major causative group for opportunistic infections (OIs). AIDS patients and other immunocompromised individuals are at risk for OIs, which if not treated appropriately, contribute to the mortality associated with their conditions. Several studies have indicated that the majority of HIV-positive patients contract fungal infections throughout the course of their disease. Similar observations have been made regarding the increased frequency of bone marrow and organ transplants, the use of antineoplastic agents, the excessive use of antibiotics, and the prolonged use of corticosteroids among others. In addition, several pathogenic fungi have developed resistance to current drugs. Together these have conspired to spur a need for developing new treatment options for OIs. To aid this effort, this article reviews the biological targets of current and emerging drugs and agents that act through these targets for the treatment of opportunistic fungal infections.
Pathogenic fungi are a major causative group for n class="Disease">opportunistic infections (OIs). AIDSpatients and other immunocompromised individuals are at risk for OIs, which if not treated appropriately, contribute to the mortality associated with their conditions. Several studies have indicated that the majority of HIV-positivepatients contract fungal infections throughout the course of their disease. Similar observations have been made regarding the increased frequency of bone marrow and organ transplants, the use of antineoplastic agents, the excessive use of antibiotics, and the prolonged use of corticosteroids among others. In addition, several pathogenic fungi have developed resistance to current drugs. Together these have conspired to spur a need for developing new treatment options for OIs. To aid this effort, this article reviews the biological targets of current and emerging drugs and agents that act through these targets for the treatment of opportunistic fungal infections.
Authors: Philipp Knechtle; Melanie Diefenbacher; Katrine B V Greve; Federico Brianza; Christophe Folly; Harald Heider; Museer A Lone; Lisa Long; Jean-Philippe Meyer; Patrick Roussel; Mahmoud A Ghannoum; Roger Schneiter; Alexandra S Sorensen Journal: Antimicrob Agents Chemother Date: 2013-11-04 Impact factor: 5.191
Authors: Barbara Higa; Bianca Souza Cintra; Carmen Magaly Álvarez; Arthur Barcelos Ribeiro; Jair Camargo Ferreira; Denise Crispim Tavares; Vanessa Enriquez; Luis R Martinez; Regina Helena Pires Journal: Med Mycol Date: 2022-08-08 Impact factor: 3.747
Authors: Christoph B Messner; Vadim Demichev; Nic Bloomfield; Jason S L Yu; Matthew White; Marco Kreidl; Anna-Sophia Egger; Anja Freiwald; Gordana Ivosev; Fras Wasim; Aleksej Zelezniak; Linda Jürgens; Norbert Suttorp; Leif Erik Sander; Florian Kurth; Kathryn S Lilley; Michael Mülleder; Stephen Tate; Markus Ralser Journal: Nat Biotechnol Date: 2021-03-25 Impact factor: 54.908